Clinical Overview
Pimobendan, a calcium sensitizer and selective phosphodiesterase-3 inhibitor with positive inotropic and vasodilatory effects, remains a cornerstone of management for canine congestive heart failure secondary to myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM), and is increasingly used off-label in feline cases.
The Compliance Challenge
Long-term CHF management depends on consistent, lifelong dosing — and compliance is frequently the limiting factor in outcomes, particularly in fractious cats, small-breed dogs requiring fractional doses, or patients with dysphagia. Commercially available tablet strengths don't always align cleanly with a patient's calculated dose, which can complicate titration.
Compounding as a Clinical Tool
PetScript Pharmacy compounds pimobendan to the exact strength your protocol calls for, in multiple delivery formats, including oral suspension for precise, titratable liquid dosing and beef-flavored quadrisect tablets for flexible fractional dosing across patient sizes. This allows you to prescribe the exact milligram strength indicated rather than rounding to the nearest commercial tablet size.
Partnering on Patient-Specific Formulations
Our clinical compounding team works directly with your practice to match strength, flavor, and delivery format to each patient's needs — supporting better adherence and more consistent therapeutic outcomes across your CHF caseload. Contact PetScript Pharmacy to discuss formulation options for your next case or to set up a standing prescribing relationship.
Learn more: visit our Pimobendan Compounding for Veterinary Cardiology page, or reach our clinical compounding team directly at info@petscript.net / 866-784-6915.
